3,4-Diaminopyridine (amifampridine) for the treatment of Lambert–Eaton myasthenic syndrome

Bibliography

• Titulaer MJ, Lang B, Verschuuren JJ. Lambert-Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies. Lancet Neurol 2011;10:1098-107
   PubMed Web of Science ®Google Scholar
• Lang B, Newsom-Davis J, Peers C, et al. The effect of myasthenic syndrome antibody on presynaptic calcium channels in the mouse. J Physiol 1987;390:257-70
   PubMedGoogle Scholar
• Oh SJ, Hatanaka Y, Claussen GC, et al. Electrophysiological differences in seropositive and seronegative Lambert-Eaton myasthenic syndrome. Muscle Nerve 2007;35:178-83
   PubMed Web of Science ®Google Scholar
• Lipka AF, Verschuuren JJ, Titulaer MJ. SOX1 antibodies in Lambert-Eaton myasthenic syndrome and screening for small cell lung carcinoma. Ann NY Acad Sci 2012;1275:70-7
   PubMedGoogle Scholar
• Molgó J, Lundh H, Thesleff S. Potency of 3,4-diaminopyridine and 4-aminopyridine on mammalian neuromuscular transmission and the effect of pH changes. Eur J Pharmacol 1980;61:25-34
   PubMed Web of Science ®Google Scholar
• Skeie GO, Apostolski S, Evoli A, et al. Guidelines for treatment of autoimmune neuromuscular transmission disorders. Eur J Neurol 2010;17:893-902
   PubMed Web of Science ®Google Scholar
• Newsom-Davis J, Murray NM. Plasma exchange and immunosuppressive drug treatment in the Lambert-Eaton myasthenic syndrome. Neurology 1984;34:480-5
   PubMed Web of Science ®Google Scholar
• Newsom-Davis J. Therapy in myasthenia gravis and Lambert-Eaton myasthenic syndrome. Semin Neurol 2003;23:191-8
   PubMed Web of Science ®Google Scholar
• Bain PG, Motomura M, Newsom-Davis J, et al. Effects of intravenous immunoglobulin on muscle weakness and calcium-channel autoantibodies in the Lambert-Eaton myasthenic syndrome. Neurology 1996;47:678-83
   PubMed Web of Science ®Google Scholar
• Maddison P. Treatment in Lambert-Eaton myasthenic syndrome. Ann NY Acad Sci 2012;1275:78-84
   PubMed Web of Science ®Google Scholar
• Wirtz PW, Titulaer MJ, van Gerven JMA, et al. 3,4-diaminopyridine for the treatment of Lambert-Eaton myasthenic syndrome. Expert Rev Clin Immunol 2010;6:867-74
   PubMed Web of Science ®Google Scholar
• Tim RW, Massey JM, Sanders DB. Lambert-Eaton myasthenic syndrome (LEMS). Clinical and electrodiagnostic features and response to therapy in 59 patients. Ann NY Acad Sci 1998;841:823-6
   PubMed Web of Science ®Google Scholar
• Maddison P, Lang B, Mills K. Long term outcome in Lambert-Eaton myasthenic syndrome without lung cancer. J Neurol Neurosurg Psychiatry 2001;70:212-17
   PubMed Web of Science ®Google Scholar
• Maddison P, McConville J, Farrugia ME, et al. The use of rituximab in myasthenia gravis and Lambert-Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry 2011;82:671-3
   PubMed Web of Science ®Google Scholar
• Pellkofer HL, Armbruster L, Linke R, et al. Managing non-paraneoplastic Lambert-Eaton myasthenic syndrome: clinical characteristics in 25 German patients. J Neuroimmunol 2009;217(1-2):90-4
   PubMedGoogle Scholar
• Harms L, Sieb JP, Williams AE, et al. Long-term disease history, clinical symptoms, health status, and healthcare utilization in patients suffering from Lambert Eaton myasthenic syndrome: results of a patient interview survey in Germany. J Med Econ 2012;15:521-30
   PubMedGoogle Scholar
• Cho S, Meriney SD. The effects of presynaptic calcium channel modulation by roscovitine on transmitter release at the adult frog neuromuscular junction. Eur J Neurosci 2006;23:3200-8
   PubMedGoogle Scholar
• Tarr TB, Valdomir G, Liang M, et al. New calcium channel agonists as potential therapeutics in Lambert-Eaton myasthenic syndrome and other neuromuscular diseases. Ann NY Acad Sci 2012;1275:85-91
   PubMedGoogle Scholar
• Quartel A, Turbeville S, Lounsbury D. Current therapy for Lambert-Eaton myasthenic syndrome: development of 3,4-diaminopyridine phosphate salt as first-line symptomatic treatment. Curr Med Res Opin 2010;26:1363-75
   PubMed Web of Science ®Google Scholar
• Huang HY, Hertting G, Allgaier C, et al. 3,4-diaminopyridine-induced noradrenaline release from CNS tissue as a model for action potential-evoked transmitter release: effects of phorbol ester. Eur J Pharmacol 1989;169:115-23
   PubMedGoogle Scholar
• Maddison P, Newsom-Davis J, Mills KR. Effect of 3,4-diaminopyridine on the time course of decay of compound muscle action potential augmentation in the Lambert-Eaton myasthenic syndrome. Muscle Nerve 1998;21(9):1196-8
   PubMedGoogle Scholar
• Lindquist S, Stangel M. Update on treatment options for Lambert-Eaton myasthenic syndrome: focus on use of amifampridine. Neuropsychiatr Dis Treat 2011;7:341-9
   PubMed Web of Science ®Google Scholar
• Wirtz PW, Verschuuren JJ, van Dijk JG, et al. Efficacy of 3,4-diaminopyridine and pyridostigmine in the treatment of Lambert-Eaton myasthenic syndrome: a randomized, double-blind, placebo-controlled, crossover study. Clin Pharmacol Ther 2009;86:44-8
   PubMed Web of Science ®Google Scholar
• Sanders DB. 3,4-diaminopyridine (DAP) in the treatment of Lambert-Eaton myasthenic syndrome (LEMS). Ann NY Acad Sci 1998;841:811-16
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Assessment report for Zenas. Procedure No.: EMEA/H/C/001032 EMA, London, UK. Available from: http://emea.europa.eu
   Google Scholar
• Verschuuren JJ, Wirtz PW, Titulaer MJ, et al. Available treatment options for the management of Lambert-Eaton myasthenic syndrome. Expert Opin Pharmacother 2006;7:1323-36
   PubMedGoogle Scholar
• Keogh M, Sedehizadeh S, Maddison P. Treatment for Lambert-Eaton myasthenic syndrome. Cochrane Database Syst Rev 2011;(2):CD003279
   Google Scholar
• McEvoy KM, Windebank AJ, Daube JR, et al. 3,4-diaminopyridine in the treatment of Lambert-Eaton myasthenic syndrome. N Engl J Med 1989;321:1567-71
   PubMed Web of Science ®Google Scholar
• Sanders DB, Massey JM, Sanders LL, et al. A randomized trial of 3,4-diaminopyridine in Lambert-Eaton myasthenic syndrome. Neurology 2000;54:603-7
   PubMed Web of Science ®Google Scholar
• Oh SJ, Claussen GG, Hatanaka Y, Morgan MB. 3,4-diaminopyridine is more effective than placebo in a randomized, double-blind, cross-over drug study in LEMS. Muscle Nerve 2009;40(5):795-800
   PubMedGoogle Scholar
• Flet L, Polard E, Guillard O, et al. 3,4-diaminopyridine safety in clinical practice: an observational, retrospective cohort study. J Neurol 2010;257:937-46
   PubMed Web of Science ®Google Scholar
• Green DM, Jones AC, Brain KR. Content variability of active drug substance in compounded oral 3,4-diaminopyridine products. J Clin Pharm Ther 2012;37:53-7
   PubMed Web of Science ®Google Scholar
• Lundh H, Nilsson O, Rosén I. Treatment of Lambert-Eaton syndrome: 3,4-diaminopyridine and pyridostigmine. Neurology 1984;34(10):1324-30
   PubMedGoogle Scholar
• Satoh K, Motomura M, Suzu H, et al. Neurogenic bladder in Lambert-Eaton myasthenic syndrome and its reponse to 3,4-diaminopyridine. Clin Auton Res 2001;11(3):145-54
   PubMedGoogle Scholar
• Mori S, Kishi M, Kubo S, et al. 3,4-diaminopyridine improves neuromuscular transmission in a MuSK antibody-induced mouse model of myasthenia gravis. J Neuroimmunol 2012;245:75-8
   PubMedGoogle Scholar
• Hoch W, McConville J, Helms S, et al. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med 2001;7:365-8
   PubMed Web of Science ®Google Scholar